Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Papathanasopoulos, P. Articles by Panagis, G. Search for Related Content PubMed Citation Articles by Papathanasopoulos, P. Articles by Panagis, G. Other Neuropsychiatric Disorders

Multiple Sclerosis, Cannabinoids, and Cognition

Received May 17, 2007; revised August 13, 2007; accepted August 14, 2007. Drs. Papathanasopoulos, Messinis, and Lyros are affiliated with the Department of Neurology, Neuropsychology Section, at the University of Patras Medical School; Drs. Kastellakis and Panagis are affiliated with the Department of Psychology, Laboratory of Behavioral Neuroscience, at the University of Crete. Address correspondence to Lambros Messinis, Ph.D., Department of Neurology, Neuropsychology Section, University of Patras Medical School, Rion, Patras, Greece; lmessinis{at}upatras.gr (e-mail).

There is increasing interest in the therapeutic potential of cannabis-based medicinal extracts in multiple sclerosis. Cognitive deficits that have been attributed to long-term heavy recreational use of cannabis are not necessarily extended to controlled pharmaceutical use of cannabis-based medicinal extracts. Available data indicate that after relatively short-term administration of cannabis-based medicinal extracts no significant cognitive decline occurs. Due to the absence of large scale long-term systematic clinical trials of cannabis-based medicinal extracts in multiple sclerosis therapeutics, however, many issues remain unresolved, including the possible adverse effects of cannabis-based medicinal extracts on cognition. This article critically reviews the current literature and considers the potential for cognitive adverse effects of long-term cannabinoid use in multiple sclerosis therapeutics.

This article has been cited by other articles:

				K. H. Taber and R. A. Hurley Endocannabinoids: Stress, Anxiety, and Fear J Neuropsychiatry Clin Neurosci, May 1, 2009; 21(2): iv - 113. [Full Text] [PDF]

				L. Messinis, P. Papathanasopoulos, A. Feinstein, and O. Ghaffar MULTIPLE SCLEROSIS AND CANNABIS: A COGNITIVE AND PSYCHIATRIC STUDY Neurology, January 6, 2009; 72(1): 100 - 101. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us